| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO | /s/ Jun Yoon, Attorney-in-Fact | 2025-07-03 | 0001962926 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GPCR | Ordinary Shares | Tax liability | -$51K | -6.44K | -3.87% | $7.92 | 160K | 01 Mar 2025 | Direct | F1, F2 |
| transaction | GPCR | Ordinary Shares | Award | $0 | +57.1K | +35.65% | $0.00 | 217K | 01 Jul 2025 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. |
| F2 | Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. |
| F3 | On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date. |